Literature DB >> 25410542

Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice.

Alessandro Guidotti1, Erbo Dong1, Patricia Tueting1, Dennis R Grayson1.   

Abstract

Based on postmortem brain studies, our overarching epigenetic hypothesis is that chronic schizophrenia (SZ) is a psychopathological condition involving dysregulation of the dynamic equilibrium among DNA methylation/demethylation network components and the expression of SZ target genes, including GABAergic and glutamatergic genes. SZ has a natural course, starting with a prodromal phase, a first episode that occurs in adolescents or in young adults, and later deterioration over the adult years. Hence, the epigenetic status at each neurodevelopmental stage of the disease cannot be studied just in postmortem brain of chronic SZ patients, but requires the use of neurodevelopmental animal models. We have directed the focus of our research toward studying the epigenetic signature of the SZ brain in the offspring of dams stressed during pregnancy (PRS mice). Adult PRS mice have behavioral deficits reminiscent of behaviors observed in psychotic patients. The adult PRS brain, like that of postmortem chronic SZ patients, is characterized by a significant increase in DNA methyltransferase 1, Tet methylcytosine dioxygenase 1 (TET1), 5-methylcytosine, and 5-hydroxymethylcytosine at SZ candidate gene promoters and a reduction in the expression of glutamatergic and GABAergic genes. In PRS mice, measurements of epigenetic biomarkers for SZ can be assessed at different stages of development with the goal of further elucidating the pathophysiology of this disease and predicting treatment responses at specific stages of the illness, with particular attention to early detection and possibly early intervention.

Entities:  

Keywords:  BDNF; Clozapine; DNA demethylase; DNA methyltransferase; GAD1; Prenatally stressed mice; RELN; S-adenosylmethionine; Schizophrenia; Valproic acid

Mesh:

Year:  2014        PMID: 25410542      PMCID: PMC4283473          DOI: 10.1016/B978-0-12-800977-2.00004-8

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  61 in total

Review 1.  Epigenetics and complex disease: from etiology to new therapeutics.

Authors:  Carolyn Ptak; Arturas Petronis
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

2.  Epigenomic profiling reveals DNA-methylation changes associated with major psychosis.

Authors:  Jonathan Mill; Thomas Tang; Zachary Kaminsky; Tarang Khare; Simin Yazdanpanah; Luigi Bouchard; Peixin Jia; Abbas Assadzadeh; James Flanagan; Axel Schumacher; Sun-Chong Wang; Arturas Petronis
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

Review 3.  Epigenetics, DNA methylation, and chromatin modifying drugs.

Authors:  Moshe Szyf
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

Review 4.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

5.  Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse.

Authors:  Patrick O McGowan; Aya Sasaki; Ana C D'Alessio; Sergiy Dymov; Benoit Labonté; Moshe Szyf; Gustavo Turecki; Michael J Meaney
Journal:  Nat Neurosci       Date:  2009-03       Impact factor: 24.884

6.  Methylation status of the reelin promoter region in the brain of schizophrenic patients.

Authors:  Mamoru Tochigi; Kazuya Iwamoto; Miki Bundo; Atsuko Komori; Tsukasa Sasaki; Nobumasa Kato; Tadafumi Kato
Journal:  Biol Psychiatry       Date:  2007-09-17       Impact factor: 13.382

7.  Induction of the reelin promoter by retinoic acid is mediated by Sp1.

Authors:  Ying Chen; Marija Kundakovic; Roberto C Agis-Balboa; Graziano Pinna; Dennis R Grayson
Journal:  J Neurochem       Date:  2007-07-31       Impact factor: 5.372

8.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars.

Authors:  Francine M Benes; Benjamin Lim; David Matzilevich; John P Walsh; Sivan Subburaju; Martin Minns
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-06       Impact factor: 11.205

9.  Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.

Authors:  Alessandro Guidotti; Erbo Dong; Marija Kundakovic; Rosalba Satta; Dennis R Grayson; Erminio Costa
Journal:  Trends Pharmacol Sci       Date:  2008-12-26       Impact factor: 14.819

10.  The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes.

Authors:  Marija Kundakovic; Ying Chen; Alessandro Guidotti; Dennis R Grayson
Journal:  Mol Pharmacol       Date:  2008-11-24       Impact factor: 4.436

View more
  10 in total

Review 1.  Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia.

Authors:  Hirofumi Morishita; Marija Kundakovic; Lucy Bicks; Amanda Mitchell; Schahram Akbarian
Journal:  Neurobiol Learn Mem       Date:  2015-04-04       Impact factor: 2.877

2.  HDAC1 links early life stress to schizophrenia-like phenotypes.

Authors:  Sanaz Bahari-Javan; Hristo Varbanov; Rashi Halder; Eva Benito; Lalit Kaurani; Susanne Burkhardt; Heike Anderson-Schmidt; Ion Anghelescu; Monika Budde; Roman M Stilling; Joan Costa; Juan Medina; Detlef E Dietrich; Christian Figge; Here Folkerts; Katrin Gade; Urs Heilbronner; Manfred Koller; Carsten Konrad; Sara Y Nussbeck; Harald Scherk; Carsten Spitzer; Sebastian Stierl; Judith Stöckel; Andreas Thiel; Martin von Hagen; Jörg Zimmermann; Antje Zitzelsberger; Sybille Schulz; Andrea Schmitt; Ivana Delalle; Peter Falkai; Thomas G Schulze; Alexander Dityatev; Farahnaz Sananbenesi; André Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

Review 3.  Epigenetic mechanisms of alcoholism and stress-related disorders.

Authors:  Martina Palmisano; Subhash C Pandey
Journal:  Alcohol       Date:  2017-03-03       Impact factor: 2.405

Review 4.  New Insights into TETs in Psychiatric Disorders.

Authors:  Wenxia Zhan; Yi Li; Jie Yuan; Na Zhi; Yiyuan Huang; Yingqi Liu; Ming Zhang; Shengxi Wu; Xianghui Zhao
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 5.  Epigenetic Basis of Mental Illness.

Authors:  Eric J Nestler; Catherine J Peña; Marija Kundakovic; Amanda Mitchell; Schahram Akbarian
Journal:  Neuroscientist       Date:  2015-10-08       Impact factor: 7.519

Review 6.  DNA Methylation in Animal Models of Psychosis.

Authors:  Dennis R Grayson; Alessandro Guidotti
Journal:  Prog Mol Biol Transl Sci       Date:  2018-03-30       Impact factor: 3.622

7.  Epigenetic landscape of stress surfeit disorders: Key role for DNA methylation dynamics.

Authors:  Eleonora Gatta; Vikram Saudagar; James Auta; Dennis R Grayson; Alessandro Guidotti
Journal:  Int Rev Neurobiol       Date:  2020-09-30       Impact factor: 3.230

8.  Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs.

Authors:  E Dong; P Tueting; F Matrisciano; D R Grayson; A Guidotti
Journal:  Transl Psychiatry       Date:  2016-01-12       Impact factor: 6.222

Review 9.  Epigenetic mechanisms involved in the effects of stress exposure: focus on 5-hydroxymethylcytosine.

Authors:  Laura M Hack; Alec L W Dick; Nadine Provençal
Journal:  Environ Epigenet       Date:  2016-08-20

10.  Ankyrin-3 as a molecular marker of early-life stress and vulnerability to psychiatric disorders.

Authors:  A Luoni; R Massart; V Nieratschker; Z Nemoda; G Blasi; M Gilles; S H Witt; M J Suderman; S J Suomi; A Porcelli; G Rizzo; L Fazio; S Torretta; A Rampino; A Berry; P Gass; F Cirulli; M Rietschel; A Bertolino; M Deuschle; M Szyf; M A Riva
Journal:  Transl Psychiatry       Date:  2016-11-08       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.